Europe Bone Degeneration Therapeutics Market: By Drug Type (Hyaluronic acid, Platelet rich plasma, Steroids and cortisone, Others),By Route of Administration (Oral, Parenteral), By Application (Osteopenia, Osteoarthritis, Spinal Fusion), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), and Homecare Settings) and by Country  

Purchase Option

$ 3000
$ 4400
$ 4600
$ 6900

Europe Bone Degeneration Therapeutics market size is valued at USD xx million in 2021 and is expected to grow at a prominent growth rate 3.8% during the forecast period 2022 to 2028. The European market provides a detailed overview of the Europe Bone Degeneration Therapeutics market, and that can be segmented by drug type, by route of administration, and by application. By drug type, The Europe Bone Degeneration Therapeutics market has been segmented into Hyaluronic acid, Platelet-rich plasma, Steroids, and cortisone, among Others. The Platelet – Rich Plasma segment is likely to be the largest and fastest-growing segment in terms of drug type. The supremacy of this segment is owing to the application of platelet-rich plasma therapy in bone degeneration disease. It was found that platelet-rich plasma therapy for curing knee osteoarthritis has a high success rate and the efficiency depends on the brutality of knee osteoarthritis. However, Cortisone or steroids is projected to grow with the fastest CAGR during the forecast period. It is mainly because corticosteroid injections can cure various spinal conditions and skeletal, and muscular. Dexamethasone, prednisone, methylprednisolone, and hydrocortisone are FDA-approved corticosteroid injections utilized to decrease inflammation and pain. Such characteristics of corticosteroid injections and their need for numerous bone diseases and injuries fuel the growth of the Bone Degeneration Therapeutics Market Share. Based on the Route of administration, the Europe Bone Degeneration Therapeutics market is segmented into Oral, Parenteral. Among these, the Parenteral segment is expected to have a significant growing market during the forecast period 2022-2028. Based on the Application, the Europe Bone Degeneration Therapeutics market is segmented into Osteopenia, Osteoarthritis, and Spinal Fusion. The Osteoarthritis segment accounts for the largest share in 2021. Based on the distribution channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, and Homecare Settings. The Hospital Pharmacies segment accounts for the largest share in 2021.

Key Developments:

In August 2021, CTI Biopharma Corporation and DRI Healthcare Trust announced the funding of pacrinitib sales and subsequent product approval by the US Food and Drug Administration (FDA). In October 2019, Amgen acquired Teneobio, Inc

Europe Bone Degeneration Therapeutics Market Summary

Study Period

2023-29

Base Year

2022

CAGR

3.8%

Largest Market

N/A

Fastest Growing Market

N/A
Europe Bone Degeneration Therapeutics Market Dynamics Drivers

Europe Bone Degeneration Therapeutics market is chiefly driven by the growing aging population and increasing cases of injuries and accidents.

Key Features of the Reports

  • The report provides granular level information about the market size, regional market share, historic market (2018 to 2022) and forecast (2023 to 2029)
  • The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The report tracks recent innovations, key developments and startup’s details that are actively working in the market
  • The report provides plethora of information about market entry strategies, regulatory framework and reimbursement scenario
  • The report analyses the impact of socio-political environment through PESTLE Analysis and competition through Porter’s Five Force Analysis in addition to recent technology advancements and innovations in the market

Europe Bone Degeneration Therapeutics Market Segmentation

drug type
  • Hyaluronic acid
  • Platelet rich plasma
  • Steroids and cortisone
  • Others
Route Administration
  • Oral
  • Parenteral
By Application
  • Osteopenia
  • Osteoporosis
  • Spinal fusion
Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

Frequently Asked Questions

The europe bone degeneration therapeutics market is projected to expand at a CAGR of 3.8% during the forecast period

Amgen, Inc. (U.S.), Bone Therapeutics SA (Belgium), Fate Therapeutics (U.S.), Regenexx (U.S.), Fate Therapeutics (U.S.), Amgen, Inc. (U.S.), Regenexx (U.S.), Bone Therapeutics SA (Belgium)

[urltag url='request-table-of-content']

  • Fate Therapeutics (U.S.)
  • Amgen, Inc. (U.S.)
  • Regenexx (U.S.)
  • Bone Therapeutics SA (Belgium)